Associated Papers
Common dihydropyrimidinase ( DPYS ) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort.
Medwid SJ et al.
Pharmacogenetics and Genomics, 2024
Functional characterization of 21 allelic variants of dihydropyrimidinase.
Hishinuma E et al.
Biochemical Pharmacology, 2017
Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity.
Hiratsuka M et al.
Plos One, 2015
Inborn errors of pyrimidine metabolism: clinical update and therapy.
Balasubramaniam S et al.
Journal of Inherited Metabolic Disease, 2014
Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients.
Fidlerova J et al.
Cancer Chemotherapy and Pharmacology, 2010
Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment.
Shimoyama S
Journal of Gastroenterology and Hepatology, 2009
Beta-alanine and beta-aminoisobutyric acid levels in two siblings with dihydropyrimidinase deficiency.
van Kuilenburg AB et al.
Nucleosides, Nucleotides & Nucleic Acids, 2008
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM et al.
Clinical Pharmacokinetics, 2006
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.
van Kuilenburg AB et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2003
Select a paper to view details